Nabriva Therapeutics plc
NBRV
株式のランク
#39896
Nabriva Therapeutics plc is a biopharmaceutical company focused on the... Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.
株価
$0.63
最終同期: 2023-08-29
時価総額
$284.20K
変化（1日）
-21.25%
変化（1年）
629,900.02%
国
IE
取引 Nabriva Therapeutics plc (NBRV)
カテゴリー
Healthcare
Nabriva Therapeutics plc（NBRV）の株価履歴
終値の最高値: $0.00 （2026-10-01）
終値の最安値: $0.74 （2023-08-01）
終値の最安値: $0.74 （2023-08-01）
Nabriva Therapeutics plc の株価履歴（2023 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | 0.00% |
| 2025 | 60.55% |
| 2024 | 9.75% |
| 2023 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $755.78 | 7.42% |
CH
|
